These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 35414658)

  • 1. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.
    Abdallah N; Murray D; Dispenzieri A; Kapoor P; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Gonsalves W; Muchtar E; Leung N; Dingli D; Kourelis T; Warsame R; Binder M; Kyle RA; Rajkumar SV; Kumar S
    Leukemia; 2022 May; 36(5):1449. PubMed ID: 35414658
    [No Abstract]   [Full Text] [Related]  

  • 2. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.
    Abdallah N; Murray D; Dispenzieri A; Kapoor P; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Gonsalves W; Muchtar E; Leung N; Dingli D; Kourelis T; Warsame R; Binder M; Kyle RA; Rajkumar SV; Kumar S
    Leukemia; 2024 Aug; 38(8):1864. PubMed ID: 38886491
    [No Abstract]   [Full Text] [Related]  

  • 3. Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.
    Abdallah N; Murray D; Dispenzieri A; Kapoor P; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Gonsalves W; Muchtar E; Leung N; Dingli D; Kourelis T; Warsame R; Binder M; Kyle RA; Rajkumar SV; Kumar S
    Leukemia; 2022 May; 36(5):1426-1428. PubMed ID: 35091659
    [No Abstract]   [Full Text] [Related]  

  • 4. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
    van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
    Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
    Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
    Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
    Eveillard M; Korde N; Ciardiello A; Diamond B; Lesokhin A; Mailankody S; Smith E; Hassoun H; Hultcrantz M; Shah U; Lu S; Salcedo M; Werner K; Rispoli J; Mastey D; Landgren O; Thoren K
    Clin Chim Acta; 2021 May; 516():136-141. PubMed ID: 33545108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
    McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
    Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis.
    Naicker SD; Feerick CL; Lynch K; Swan D; McEllistrim C; Henderson R; Leonard NA; Treacy O; Natoni A; Rigalou A; Cabral J; Chiu C; Sasser K; Ritter T; O'Dwyer M; Ryan AE
    Oncoimmunology; 2021 Jan; 10(1):1859263. PubMed ID: 33552684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using
    Li S; England CG; Ehlerding EB; Kutyreff CJ; Engle JW; Jiang D; Cai W
    Am J Transl Res; 2019; 11(9):6007-6015. PubMed ID: 31632568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.
    Thoren KL; Pianko MJ; Maakaroun Y; Landgren CO; Ramanathan LV
    J Appl Lab Med; 2019 Mar; 3(5):857-863. PubMed ID: 31639760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
    Clemens PL; Yan X; Lokhorst HM; Lonial S; Losic N; Khan I; Jansson R; Ahmadi T; Lantz K; Zhou H; Puchalski T; Xu XS
    Clin Pharmacokinet; 2017 Aug; 56(8):915-924. PubMed ID: 27896689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring.
    Liu L; Wertz WJ; Kondisko A; Shurin MR; Wheeler SE
    J Appl Lab Med; 2020 Jan; 5(1):29-40. PubMed ID: 32445341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Development of CD38-Targeted [
    Ghai A; Maji D; Cho N; Chanswangphuwana C; Rettig M; Shen D; DiPersio J; Akers W; Dehdashti F; Achilefu S; Vij R; Shokeen M
    J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daratumumab-
    Dawicki W; Allen KJH; Jiao R; Malo ME; Helal M; Berger MS; Ludwig DL; Dadachova E
    Oncoimmunology; 2019; 8(8):1607673. PubMed ID: 31413916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.
    Usmani SZ; Khan I; Chiu C; Foureau D; Druhan LJ; Rigby K; Casneuf T; Sasser AK
    Exp Hematol Oncol; 2018; 7():3. PubMed ID: 29445583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
    Plesner T; van de Donk N; Richardson PG
    Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
    Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
    Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.
    Michaleas S; Penninga E; Hovgaard D; Dalseg AM; Rosso A; Sarac SB; Jimenez JC; Fernández LL; Fernández CP; Mangas-SanJuan V; Garcia I; Payares-Herrera C; Sancho-López A; Enzmann H; de Castro Lopes Silva MSS; Duarte S; Pignatti F
    Oncologist; 2020 Dec; 25(12):1067-1074. PubMed ID: 33026700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR.
    Zeng X; Peng L; Peng Y; Tan C; Wan X
    Clin Ther; 2020 Feb; 42(2):251-262.e5. PubMed ID: 31973936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
    Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
    Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.